Clinical Trial Update: Myrcludex B Plus Pegylated Interferon-alpha-2a in Patients With HBeAg Negative HBV/HDV Co-infection [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial of Myrcludex B plus pegylated interferon-alpha-2a in HBV/HDV co-infection has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis D

Drugs mentioned

• Myrcludex B (bulevirtide)
• Pegylated Interferon Alpha-2a (pegylated interferon alfa-2a)

Snippet

Sponsor: Hepatera Ltd. | Conditions: Chronic Hepatitis D Infection | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2018-04-13